Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0.0183150183150184 0.0884615384615386
Stock impact report

NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells

NantKwest, Inc (NK)  More Company Research Source: Business Wire
Last nantkwest, inc earnings: 3/25 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nantkwest.com
PDF Clinical trial for patients failing checkpoint therapy uses combination of first-in-class, cryopreserved, CD16 NK cells, ImmunityBio’s IL-15 superagonist and checkpoint inhibitor Avelumab EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer and infectious diseases, today announced dosing of the first patient in a Phase 2 trial for second- and third-line Merkel cell carcinoma (MCC) in patients who are refractory to immune checkpoint inhibitors. The trial will evaluate the Company’s first-in-class, off-the-shelf CD16-targeted natural killer (haNK) cells in combination with ImmunityBio’s IL-15 superagonist N-803 and Avelumab.MCC is a rare and aggressive skin cancer that arises from uncontrolled growth of cells in the skin. Increasing in incidence, approximately 2,500 new cases are reported in the U.S. each yea [Read more]
Impact snapshot Event time: NK
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
NK alerts
from News Quantified
Opt-in for
NK alerts

from News Quantified
Opt-in for
NK alerts

from News Quantified